author-photo

Meaghan Granger

Boston Children's Hospital

21

Papers

199

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Changes in ctDNA levels after MIBG therapy in patients with relapsed or refractory neuroblastoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Predicting response to chemotherapy in neuroblastoma using deep learning: A report from the International Neuroblastoma Risk Group.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group (COG) trial ANBL12P1

2021
Show All
- Source
- Cite
- Save
Citations (2)
Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for resistant/relapsed neuroblastoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)

2019 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (19)
A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (38)
Comparison of Taqman low density array (TLDA) five-gene assay for tumor cells in bone marrow and blood with histologic bone marrow examination and imaging for disease assessment and outcome in patients with recurrent/refractory neuroblastoma (NBL): A new approaches to neuroblastoma therapy (NANT) study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)